Loading...
•
Jun 30, 2021
Arvinas Q2 2021 Earnings Report
Arvinas' financial results for Q2 2021 were reported, and a corporate update was provided.
Key Takeaways
Arvinas reported a net loss of $50.3 million for the second quarter of 2021, compared to a net loss of $25.2 million for the same period in 2020. Revenue was $5.5 million, slightly less than the $5.7 million reported in the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $605.1 million as of June 30, 2021.
Arvinas announced a global collaboration with Pfizer to co-develop and co-commercialize ARV-471.
The first-in-human study of ARV-766 was initiated.
Dose escalation was completed in the Phase 1 study of ARV-471.
Dose escalation was completed in the Phase 1 study of ARV-110.
Forward Guidance
Arvinas anticipates several milestones and expectations for ARV-471 and ARV-110 in the second half of 2021.
Positive Outlook
- Presentation of Phase 1 dose escalation trial data for ARV-471 at the San Antonio Breast Cancer Symposium in December 2021.
- Initiation of a neoadjuvant study in early breast cancer for ARV-471 in 2H21.
- Initiation of a combination trial of ARV-471 and everolimus in 2L/3L metastatic breast cancer in 2H21.
- Presentation of completed Phase 1 dose escalation data for ARV-110 in 2H21.
- Presentation of interim data from the ARDENT Phase 2 dose expansion at 420 mg for ARV-110 in 2H21.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...